Stock market today: S&P 500 closes at fresh record ahead of Nvidia earnings
Investing.com -- Kiora Pharmaceuticals Inc (NASDAQ:KPRX) stock rose 2.3% after the company announced it has received a new patent covering its KIO-104 treatment for various ocular diseases.
The patent (US Patent No. 12,364,680) covers the use of KIO-104 for treating conditions including ocular inflammation, uveitis, age-related macular degeneration, and complications from refractive surgery. It also protects varying dosing schedules and formulation methods, extending market exclusivity until 2043.
"Securing this patent builds on our IP strategy to protect KIO-104 around its proprietary structure, delivery methods, formulation, and therapeutic applications," said Brian M. Strem, President & CEO of Kiora Pharmaceuticals. "This specific patent is significant in its breadth of therapeutic applications."
KIO-104 is a small molecule being developed as an alternative to steroids or systemic anti-inflammatory drugs for inflammatory retinal diseases. The company is currently conducting the KLARITY study, a Phase 2 clinical trial investigating KIO-104 in up to 28 patients with conditions such as posterior non-infectious uveitis and diabetic macular edema.
The treatment works by inhibiting the mitochondrial enzyme DHODH, which plays a key role in T-cell replication and function. By reducing the availability of DNA and RNA building blocks, KIO-104 aims to dampen T-cell-driven inflammation in the eye.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.